Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma
US6896885B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Apr 2, 2001 |
| Grant date | May 24, 2005 |
| Priority date | — |
| Expiry date | Apr 2, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention discloses combined therapies for treating hematologic malignancies, including B cell lymphomas and leukemias or solid non-hematologic tumors, comprising administration of anti-cytokine antibodies or antagonists to inhibit the activity of cytokines which play a role in perpetuating the activation of B cells. The administration of such antibodies and antagonists, particularly anti-IL10 antibodies and antagonists, is particularly useful for avoiding or decreasing the resistance of hematologic malignant cells or solid tumor cells to chemotherapeutic agents and anti-CD20 or anti-CD22 antibodies.The invention also provides combination therapies for solid tumors having B cell involvement comprising the administration of an anti-cytokine antibody and a B cell depleting antibody such as RITUXAN® (rituximab).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.